)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Beximco Pharmaceuticals
Beximco Pharmaceuticals (BXP) investor relations material
Beximco Pharmaceuticals has been delisted
Beximco Pharmaceuticals H1 24/25 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 24/25 earnings summary28 Jan, 2025
Executive summary
Net revenue for July–December 2024 rose to Tk 24,013 million (consolidated), up 8.8% year-over-year; standalone revenue reached Tk 19,952 million, up 8.9%.
Consolidated net profit after tax increased 17.5% year-over-year to Tk 3,535 million; standalone net profit rose 18.1% to Tk 3,421 million.
Earnings per share (EPS) improved to Tk 7.87 (consolidated) and Tk 7.67 (standalone), compared to Tk 6.69 and Tk 6.49, respectively, in the prior year.
Financial highlights
Consolidated gross profit margin was 45.7%, up from 44.4% year-over-year; standalone gross margin was 45.5%.
Operating profit (consolidated) increased 12% to Tk 5,088 million; standalone operating profit rose 13.5% to Tk 4,539 million.
Net asset value (NAV) per share reached Tk 111.35 (consolidated) and Tk 109.90 (standalone), up from Tk 101.11 and Tk 100.15, respectively.
Net operating cash flow per share declined to Tk 6.13 (consolidated) and Tk 5.34 (standalone), compared to Tk 10.01 and Tk 9.54 in the prior year.
Outlook and guidance
Management notes operating cash flow per share declined due to higher working capital needs, mainly from strategic inventory buildup.
No forward-looking revenue or profit guidance provided; focus remains on domestic and international market expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Beximco Pharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Beximco Pharmaceuticals Limited, also known as Beximco Pharma, is a prominent pharmaceutical company based in Bangladesh, part of the Bangladesh Export Import Company Limited (BEXIMCO). Established in 1980, Beximco Pharma has grown to manufacture and market its own branded generics for various diseases including AIDS, cancer, asthma, hypertension, and diabetes, catering to both national and international markets. It holds the distinction of being the first drug company from Bangladesh to sell its products in the US market. The company operates out of its headquarters in Dhanmondi, Dhaka, Bangladesh, and its shares are listed on the Dhaka Stock Exchange and the London Stock Exchange.